{"id":19792,"date":"2021-09-27T13:53:35","date_gmt":"2021-09-27T18:53:35","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/ecd-staging\/?post_type=study_trials&#038;p=19792"},"modified":"2021-09-27T13:54:50","modified_gmt":"2021-09-27T18:54:50","slug":"%d7%9e%d7%99%d7%a0%d7%95%d7%9f-%d7%a0%d7%9e%d7%95%d7%9a-%d7%a9%d7%9c-%d7%a1%d7%9c%d7%99%d7%a0%d7%a7%d7%a1%d7%95%d7%a8-%d7%95%d7%a1%d7%9c%d7%99%d7%a6%d7%99%d7%9c%d7%98-%d7%9b%d7%95%d7%9c%d7%99%d7%9f","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/he\/study_trials\/low-dose-selinexor-and-choline-salicylate-for-the-treatment-of-patients-with-residual-relapsed-or-refractory-non-hodgkin-lymphoma\/","title":{"rendered":"\u05e1\u05dc\u05d9\u05e0\u05e7\u05e1\u05d5\u05e8 \u05d1\u05de\u05d9\u05e0\u05d5\u05df \u05e0\u05de\u05d5\u05da \u05d5\u05e1\u05dc\u05d9\u05e6\u05d9\u05dc\u05d8 \u05db\u05d5\u05dc\u05d9\u05df \u05dc\u05d8\u05d9\u05e4\u05d5\u05dc \u05d1\u05d7\u05d5\u05dc\u05d9\u05dd \u05e2\u05dd \u05dc\u05d9\u05de\u05e4\u05d5\u05de\u05d4 \u05e9\u05d0\u05d9\u05e0\u05d4 \u05d4\u05d5\u05d3\u05d2'\u05e7\u05d9\u05df \u05e9\u05d9\u05d5\u05e8\u05d9\u05ea, \u05d7\u05d5\u05d6\u05e8\u05ea \u05d0\u05d5 \u05e2\u05de\u05d9\u05d3\u05d4 \u05dc\u05d8\u05d9\u05e4\u05d5\u05dc"},"content":{"rendered":"<p><strong>\u05de\u05d8\u05e8\u05ea \u05d4\u05de\u05d7\u05e7\u05e8:<\/strong> \u05dc\u05d4\u05e2\u05e8\u05d9\u05da \u05d0\u05ea \u05d4\u05de\u05d9\u05e0\u05d5\u05df \u05d4\u05de\u05e8\u05d1\u05d9 \u05e0\u05e1\u05d1\u05dc (MTD) \u05e9\u05dc \u05e1\u05dc\u05d9\u05e6\u05d9\u05dc\u05d8 \u05db\u05d5\u05dc\u05d9\u05df (CS) \u05e9\u05e0\u05d9\u05ea\u05df \u05dc\u05e9\u05dc\u05d1 \u05e2\u05dd \u05e1\u05dc\u05d9\u05e0\u05e7\u05e1\u05d5\u05e8 \u05e4\u05e2\u05de\u05d9\u05d9\u05dd \u05d1\u05e9\u05d1\u05d5\u05e2 \u05d1\u05e7\u05e8\u05d1 \u05d7\u05d5\u05dc\u05d9\u05dd \u05d4\u05e1\u05d5\u05d1\u05dc\u05d9\u05dd \u05de\u05dc\u05d9\u05de\u05e4\u05d5\u05de\u05d4 \u05de\u05e4\u05d5\u05e9\u05d8\u05ea \u05e9\u05dc \u05ea\u05d0\u05d9 B \u05d2\u05d3\u05d5\u05dc\u05d9\u05dd (DLBCL) \u05d0\u05d5 \u05dc\u05d9\u05de\u05e4\u05d5\u05de\u05d4 \u05e9\u05dc \u05ea\u05d0\u05d9 \u05d4\u05de\u05e2\u05d8\u05e4\u05ea (MCL) \u05e2\u05dd \u05d4\u05d9\u05e9\u05e0\u05d5\u05ea \u05d0\u05d5 \u05e2\u05de\u05d9\u05d3\u05d5\u05ea \u05dc\u05d8\u05d9\u05e4\u05d5\u05dc. (\u05d9\u05e2\u05d3 \u05e8\u05d0\u05e9\u05d9)<\/p>\n<p><strong>\u05d7\u05d5\u05e7\u05e8 \u05e8\u05d0\u05e9\u05d9:<\/strong> &nbsp;\u05d3\"\u05e8 \u05d2'\u05d5\u05e0\u05d0\u05e1 \u05e4\u05d0\u05dc\u05d5\u05d3\u05d5, \u05de\u05e8\u05e4\u05d0\u05ea \u05de\u05d0\u05d9\u05d5 \u05d1\u05e8\u05d5\u05e6'\u05e1\u05d8\u05e8, \u05de\u05d9\u05e0\u05e1\u05d5\u05d8\u05d4, \u05d0\u05e8\u05e6\u05d5\u05ea \u05d4\u05d1\u05e8\u05d9\u05ea<\/p>\n<p><strong>\u05e4\u05e8\u05d8\u05d9 \u05d9\u05e6\u05d9\u05e8\u05ea \u05e7\u05e9\u05e8:<\/strong> \u05de\u05e9\u05e8\u05d3 \u05d4\u05d4\u05e4\u05e0\u05d9\u05d4 \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9\u05d9\u05dd \u05e7\u05dc\u05d9\u05e0\u05d9\u05d9\u05dd   \u05d8\u05dc\u05e4\u05d5\u05df: +1-855-776-0015   \u05d3\u05d5\u05d0\"\u05dc: <a href=\"mailto:mayocliniccancerstudies%40mayo.edu?subject=NCT04640779,%20LS1981,%20Low-Dose%20Selinexor%20and%20Choline%20Salicylate%20for%20the%20Treatment%20of%20Patients%20With%20Residual,%20Relapsed%20or%20Refractory%20Non-Hodgkin%20Lymphoma\">mayocliniccancerstudies@mayo.edu<\/a>&nbsp;&nbsp;<\/p>\n<p><strong>\u05de\u05e2\u05d5\u05e8\u05d1\u05d5\u05ea \u05d4\u05de\u05d8\u05d5\u05e4\u05dc \u05d4\u05e0\u05d3\u05e8\u05e9\u05ea:<\/strong> \u05de\u05d2\u05d9\u05dc 18 \u05d5\u05de\u05e2\u05dc\u05d4&nbsp;<\/p>\n<p><strong>\u05de\u05d6\u05d4\u05d4 \u05d1\u05d0\u05ea\u05e8 ClinicalTrials.gov:<\/strong> NCT04640779<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: To evaluate the maximum tolerated dose (MTD) of choline salicylate (CS) that can be combined with selinexor twice weekly in patients with relapsed\/refractory diffuse large B cell lymphoma [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32,129],"class_list":["post-19792","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial","study_trials_cat-interventional"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/study_trials\/19792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/media?parent=19792"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/study_trials_cat?post=19792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}